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INTRODUCTION
In most cases of lung transplantation, immunosuppression is maintained using calcineurin inhibitors (CNIs), anti-metabolites and steroids. Lung transplant recipients on such a regimen of triple immunosuppressants are susceptible to infectious diseases.
Moreover, many prophylactic antibiotics and laboratory studies are needed, including monitoring of immunosuppressant levels and respiratory function tests, to prevent or predict allograft rejection. However, serum immunosuppressant levels alone may not accurately reflect immune status. ImmuKnow® (Cylex, Columbia, MD) is a novel and promising in vitro assay for measuring the cell function of stimulated T cells. 1 Bhorade et al. 2 reported that ImmuKnow® levels were lower in lung transplant recipients with infection than in non-infected recipients. We report two clinical cases in which mycofenolate mofetil (MMF) was successfully withdrawn after living donor lobar lung transplantation while monitoring patient immune function with the ImmuKnow® assay.
after transplantation, the patient developed invasive pulmonary aspergillosis (IPA). MMF was withdrawn immediately, and the trough level of tacrolimus was reduced to around 5-8 ng/ml to allow the immune status of the patient to recover and battle this fatal infection. The patient was treated with oral voricocazole at 300 mg twice daily, inhalation of amphotericin B at 10 mg 5 times daily, and intravenous micafungin at 300 mg/day.
Fortunately, her condition improved over 3 months of hospitalization, and she was discharged without any symptoms. Oral voriconazole and inhaled amphotericin B were continued as prophylaxis for 9 months. Details of the clinical course have been reported previously. 3 Immune function in this patient was monitored using the ImmuKnow® assay from 14 to 37 months after transplantation ( 
Case 2
A 24-year-old man underwent LDLLT for cystic fibrosis. He had paranasal sinusitis, but curative surgery had already been performed before transplantation. The left lower lobe was donated by his father, while the right lower lobe was donated by his uncle. After LDLLT, primary graft dysfunction occurred in the left lung due to the some influence of mild alcoholic liver cirrhosis. As a result, immediate single lobar re-transplantation was performed using the left lower lobe donated by his sister. 4 Postoperative course after the redo operation was uneventful, and the patient was discharged without any oxygen support. He had been receiving treatment under the same strategy seen in Case 1, with a standard triple immunosuppressive and prophylactic regimen for infectious disease. Several limitations must be considered when interpreting the present findings.
Follow-up in these case reports was short and immune function is very complicated, so evaluation of CD4 + T-cell function alone is not necessarily representative of total immune function in each patient. Another problem is that, in general, most LDLLTs are undertaken between relatives and extensive immunological matching may take place beforehand to select the most appropriate donor. Such practices might have contributed to the ability to maintain moderate immune function without MMF in the present cases.
In conclusion, immune evaluation using ImmuKnow® could be useful for monitoring immune status in patients. Although this report describes only two cases and follow-up was short, this method showed that moderate immune status can be maintained using only two immunosuppressants in some patients after LDLLT, reducing susceptibility to infectious disease. Further study is needed to determine the scope of the role ImmuKnow® can play in optimizing the immune status of lung transplant patients.
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Horizontal lines represent cut-off levels for strong (ATP, over 525 ng/ml), moderate (ATP, 524-226 ng/ml), and low immune function (ATP, under 225 ng/ml). IPA, invasive pulmonary aspergillosis. ATP, adenosine triphosphate 
